secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001193125-25-044876
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences Q4 net income $29.3M; cash $302M; obesity and AATD data expected in 2025
--------------------------------------------------------------------------------

- Q4 2024 revenue $83.7M (up from $29.1M YoY); net income $29.3M vs prior year net loss $16.3M.
- Full year 2024 net loss $97.0M, compared to $57.5M in 2023; R&D expenses increased to $159.7M.
- Cash $302.1M as of Dec 31, 2024, expected operating runway into 2027; excludes potential GSK milestones.
- Dosing underway in INLIGHT trial of WVE-007 in obesity; clinical data expected 2H 2025.
- On track to deliver FORWARD-53 48-week DMD data and FDA feedback on accelerated approval in 1Q 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525044876/0001193125-25-044876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525044876/d785711d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-044876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer